Oncology Medical News about soft tissue leiomyosarcoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma
Modern Pathology, 07/28/09

Tsiatis AC et al. – Detection of nuclear c–Myc in leiomyosarcoma predicts decreased overall and metastasis–free survival, independent of standard prognostic variables, tumor size, histological grade, and TNM stage. The expression of this oncoprotein may represent a useful prognostic marker and potential therapeutic target in leiomyosarcoma.

Exclusive Author Commentary
AC Tsiatis, 07/30/09

Making treatment decisions for patients with leiomyosarcoma is complicated by the clinical heterogeneity that exists within this patient population. Although clinical and pathologic parameters are used to define poor, intermediate, and good prognosis groups, these definitions are inadequate, as patient outcomes are diverse and difficult to predict even within these prognostic groups. Our results suggest that c-Myc may be an important factor in further defining the prognosis for individual patients with this rare tumor type. More importantly, these results implicate c-Myc as a pharmaco-therapeutic oncogenic target. Based on these preliminary data, collaborative studies, including clinical trials, may now be designed to assess the clinical utility of anti-c Myc pharmacotherapeutics currently under investigation or in development. It is our hope that this study will lead to the optimization of current treatment protocols and the design of novel therapeutic regimens for patients with c Myc-positive soft tissue leiomyosarcoma and provide our patients with much needed hope for substantial, efficacious treatment options.

<< Previous
Gene expression profiles of ductal versus acinar adenocarcinoma...

Next >>
Characterization of candidate gene copy number alterations in the...